Fig. 2

Forest plots of direct comparisons for pCR. (a) T-DM1 vs. HP + C; (b) HP + C vs. H + C; (c) H + TKI + C vs. H + C; (d) H + TKI + C vs. L + C; (e) L + C vs. H + C; (f) C vs. H + C. T-DM1 = trastuzumab emtansine based regimens; HP + C = trastuzumab and pertuzumab with chemotherapy; H + TKI + C = trastuzumab and TKI with chemotherapy; H + C = trastuzumab with chemotherapy; L + C = lapatinib with chemotherapy; C = chemotherapy with no HER2-targeting regimen. The squares and the lines crossing the square stand for OR and its 95%CI. The diamonds stand for the estimated pooled OR and its 95% CI. Heterogeneity was tested with Cochran’s Q test, and all statistical tests were two-sided.